OPK - יחס חוב להיוון בספרים OPKO Health Corp.

The product portfolio of OPKO Health, Inc. (OPK) in diagnostics and pharmaceuticals has reached the maturity stage, yet low profitability and competition are weighing on the business. Current price action, reaching 0.34, is accompanied by management efforts to consolidate holding assets to launch new tests into the market. Development relies on partnerships with pharma behemoths, where BioReference provides the research base for creating innovative medications.

This indicator assesses the ratio of total credit liabilities to equity, determining the company's degree of dependence on borrowed funds and the stability of its financial leverage. Analyzing the structure of debt obligations relative to book capitalization reveals how effectively OPKO Health, Inc. (OPK) finances its diagnostics and therapeutics ecosystem, balancing debt load against investments in innovative drugs.